Observational studyBMC infectious diseases2025
Long-term trends in reporting of cardiac adverse drug reactions to COVID-19 vaccines - an exploratory analysis of the EudraVigilance database.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaccination against COVID-19 could be followed by a serious cardiac adverse drug reaction (SCADR), which is a noxious, unintended response to the administered vaccine and is life-threatening, usually requires hospitalisation and may result in death. We aimed to explore long-term trends in reporting of SCADRs to COVID-19 vaccines.
methodsIn this retrospective, longitudinal, observational study, suspected (potentially linked to vaccination) SCADRs to Comirnaty (Pfizer BioNTech), Spikevax (Moderna), Vaxzevria (AstraZeneca) and Jcovden (Janssen) vaccines were extracted from the EudraVigilance database (n = 87,000). This data was coupled with the corresponding weekly number of administered vaccine doses from the Vaccine Tracker database (n = 733,837,251).
resultsThe most frequently documented categories of SCADRs included arrhythmia (n = 29,936), thrombosis (n = 21,381), inflammation (myocarditis and pericarditis, n = 13,421), blood pressure abnormalities (n = 10,535) and syncopes (n = 10,363), both during the first year and for the whole vaccination period. During the first year of vaccine distribution, the total number of SCADRs per million administered vaccine doses was 77.3 (Comirnaty), 76.4 (Spikevax), 115.3 (Jcovden) and 230.3 (Vaxzevria). These values changed significantly when the whole period of vaccinations was considered (145.6, 146.3, 203.5, 320.5, respectively; p < 0.001). Concerning vaccine administration timelines, the reporting of suspected adverse drug reactions appears to be more widely distributed over time (p < 0.05).
conclusionsThe frequency of reporting suspected SCADRs after COVID-19 vaccinations appears to change dynamically over time. Concerning the administration of vaccine doses, the reporting of potential post-vaccination ADRs seems to be more distributed in time. These observations suggest that post-approval long-term monitoring of suspected ADRs may be valuable for improving data capture and supporting vaccine safety assessment. This underlines the potential importance of comprehensive surveillance in the context of infectious diseases and vaccine development programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.